surgery

Surgeon who chairs the German AGO group and led DESKTOP III, proving secondary surgery can extend survival in selected relapsed ovarian cancer.

Brazilian surgeon who first showed that rectal cancers that vanish after chemoradiation can be watched rather than removed.

Canadian surgeon who led ORATOR, the first randomised trial to compare robotic surgery with radiotherapy for early throat cancer, which found swallowing was slightly better after radiotherapy.

Brought sentinel node biopsy to breast cancer and led ACOSOG Z0011, which ended routine axillary dissection for many women.

Surgeon who led CARMENA, the trial that showed most metastatic kidney cancer patients do not benefit from removing the kidney.

Urologist who set the definitions for BCG-unresponsive bladder cancer and leads the International Bladder Cancer Group.

Surgeon who led the Dutch TME trial, proving standardised rectal surgery with radiotherapy cuts local recurrence.

Led CONFIRM and MARS 2, which showed nivolumab helps relapsed mesothelioma and that radical surgery does not.

Urologist who co-led proPSMA, the trial that showed PSMA PET should replace CT and bone scan for staging prostate cancer.

Surgeon-scientist who led the TCGA endometrial cancer study that created today's four molecular subtypes.

Duke surgeon who led COMET, the trial testing whether women with low-risk DCIS can safely be monitored instead of having surgery straight away.

Surgeon who chairs the NRG Oncology breast committee and co-led the KATHERINE and B-42 trials.

Surgeon-scientist who led IMpassion031 and studies of surgery de-escalation after neoadjuvant immunotherapy.

Led ProtecT, the trial that showed monitoring, surgery and radiotherapy give equally low prostate cancer death rates at 15 years.

Surgeon who led De-ESCALaTE and PET-NECK, two trials that changed how HPV-positive throat cancer is treated and followed up.

Japanese surgeon who led JCOG0912, the trial that confirmed laparoscopic gastrectomy is not inferior to open surgery for early stomach cancer.

Korean surgeon who led KLASS-01, the trial that showed keyhole gastrectomy is as safe and effective as open surgery for early stomach cancer.

Surgeon who led the CROSS trial, which made chemoradiotherapy before surgery the standard for oesophageal cancer.

Houston surgeon who chaired the melanoma expert panel for the eighth edition of the AJCC staging system, the classification doctors use to describe how far a melanoma has spread.

German surgeon who led ESOPEC, the trial that compared FLOT chemotherapy with CROSS chemoradiotherapy before surgery for oesophageal adenocarcinoma and found FLOT gave longer survival.

British surgeon who led BILCAP, the trial that made six months of capecitabine the standard after surgery for bile duct and gallbladder cancer.

The surgeon on CheckMate 816 who showed neoadjuvant immunotherapy does not make lung cancer operations harder.

Surgeon who led OPRA, showing half of rectal cancer patients can keep their rectum with total neoadjuvant therapy and watch-and-wait.

Dutch surgeon who leads the PREOPANC trials testing chemotherapy or chemoradiation before pancreatic cancer surgery.

Quebec surgeon who pioneered fertility-sparing surgery for cervical cancer and led SHAPE, the trial that showed a simple hysterectomy is enough for low-risk early cervical cancer.

Surgeon who led MSLT-II, showing that removing all lymph nodes after a positive sentinel node does not improve melanoma survival.

Endocrine surgeon who leads Rambam Health Care Campus, the largest hospital in northern Israel, after nearly three decades at the institution.

Neurosurgeon who proved that removing more of a glioma extends survival and pioneered awake mapping to do it safely.

Japanese surgeon whose JCOG trials defined D2 gastrectomy and adjuvant S-1 as standards for gastric cancer.

Breast surgeon whose margin and axillary guidelines cut unnecessary re-excisions and lymph node surgery worldwide.

Houston surgeon who led the trial showing that giving cemiplimab before surgery can eliminate cutaneous squamous-cell carcinoma in about half of patients, sparing many from extensive operations.

Surgeon who led the LACC trial, which unexpectedly showed keyhole hysterectomy worsens survival in early cervical cancer.

Polish surgical oncologist who led the pooled EORTC and SWOG trials showing that imatinib shrinks dermatofibrosarcoma protuberans, a rare skin sarcoma driven by a PDGFB fusion.

Surgeon-scientist who led the first neoadjuvant pembrolizumab trial in head and neck cancer and the KEYNOTE-689 study that made it standard.

Gynaecologic oncologist who led ARIEL3 and GOG-0213, shaping PARP maintenance and secondary surgery in relapsed ovarian cancer.

Surgeon and immunologist who led CheckMate 141, the trial that made nivolumab the first drug to lengthen survival in head and neck cancer after platinum failure, and E3311 on transoral surgery for HPV-positive throat cancer.

American surgeon who pioneered removing the thyroid in children with inherited RET mutations before cancer develops, led ZETA, the trial that established vandetanib for medullary thyroid cancer, and chaired the American Thyroid Association guideline for the disease.

Mayo Clinic urologist who led the trial of nadofaragene firadenovec, the first gene therapy approved for bladder cancer that no longer responds to BCG.

Paris surgeon who championed compartmental resection for retroperitoneal sarcoma and led STRASS, the trial that showed preoperative radiotherapy does not improve abdominal recurrence-free survival overall.

Thoracic surgeon who led the IASLC staging projects that define how lung cancer and mesothelioma are staged.

Led OVHIPEC-1, the trial that showed heated intraperitoneal chemotherapy at surgery extends survival in ovarian cancer.

Japanese surgeon who was lead author of CheckMate 648, which established nivolumab-based first-line treatment for advanced oesophageal squamous-cell carcinoma.

Liver surgeon who defined who benefits from resecting colorectal liver metastases and pioneered oncolytic virus therapy.